部分肠内营养联合奥曲肽治疗肝硬化乳糜性腹水1例报告

doi:10.3969/j.issn.1672-5069.2023.02.035

Abstract

Huang Shulun, He Shengduo, Xu Xiaoyuan, et al.. Efficacy of partial enteral nutrition and octreotide treatment for liver cirrhotic patient with chylous ascites:a case report[J]. Journal of Practical Hepatology, 2023, 26(2): 290-292.

References

[1] Lizaola B, Bonder A, Trivedi HD, et al. The diagnostic approach and current management of chylous ascites. Aliment Pharmacol Ther, 2017, 46(9): 816-824.
[2] Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int, 2018, 38(4): 570-580.
[3] Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology, 2003, 38(6): 1508-1515.
[4] 韩涛, 聂彩云. 肝硬化腹水发病机制研究现状. 实用肝脏病杂志, 2014, 17(4): 4.
[5] Ribera J, Pauta M, Melgar-Lesmes P, et al. Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut, 2013, 62(1): 138-145.
[6] Hashim SA, Roholt HB, Babayan VK, et al. Treatment ofchyluria and chylothorax with medium-chain triglyceride. N Engl J Med, 1964, 270: 756-761.
[7] Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med, 1982, 96(3): 358-364.
[8] Bhardwaj R, Vaziri H, Gautam A, et al. Chylousascites: A review of pathogenesis, diagnosis and treatment. J Clin Transl Hepatol, 2018, 6(1): 105-113.
[9] Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med, 2006, 12(4): 264-267.
[10] Ahn D, Jeon J H, Kim H, et al. Effect of octreotide injection on postoperative drainage after neck dissection: A preliminary report of a prospective, matched case-control study. Clin Exp Otorhinolaryngol, 2016, 9(2): 173-177.
[11] Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology, 2001, 120(4): 946-954.
[12] Cui PJ, Yao J, Zhu Y, et al. Effects of along-acting formulation of octreotide on patients with portal hypertension. Gastroenterol Res Pract, 2017, 2017: 1-6.
[13] Spahr L, Giostra E, Frossard JL, et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol, 2007, 102(7): 1397-1405.
[14] Chandok N, Kamath PS, Blei A, et al. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther, 2012, 35(8): 904-912.
[15] Zhang L, Wang X, Chen S, et al. Medium-chain triglycerides attenuate liver injury in lipopolysaccharide-challenged pigs by inhibiting necroptotic and inflammatory signaling pathways. Int J Mol Sci, 2018, 19(11): 3697.
[16] Singh H, Pandit N, Krishnamurthy G, et al. Management of chylous ascites following pancreaticobiliary surgery. JGH Open, 2019, 3(5): 425-428.
[17] Zheng J, Chen YY, Zhang CY, et al. The retrospective research of enteral nutrition with medium-chain triglyceride and total parenteral nutrition support of postoperative chylothorax in adults. SAGE Open Med, 2020, 8: 325.
[18] Zheng J, Chen YY, Zhang CY, et al. Incidence and nutritional management of chylothorax after surgery for congenital heart diseases in children. Heart Surg Forum, 2020, 23(6): E902-E906.
[19] Tulunay G, Ureyen I, Turan T, et al. Chylous ascites: analysis of 24 patients. Gynecol Oncol, 2012, 127(1): 191-197.
[20] Ijichi H, Soejima Y, Taketomi A, et al. Successful management of chylous ascites after living donor liver transplantation with somatostatin. Liver Int, 2008, 28(1): 143-145.
[21] 胡丽娟, 王丽晶, 简易成, 等. 奥曲肽治愈肝硬化乳糜性腹水1例并文献复习. 临床肝胆病杂志, 2012, 28(8): 624-625.
[22] 张海静, 王文睿, 杨岚岚, 等. 奥曲肽治疗肝硬化乳糜样腹水1例. 中南药学, 2019, 17(5): 775-776.

Efficacy of partial enteral nutrition and octreotide treatment for liver cirrhotic patient with chylous ascites:a case report

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yin Wen, Lu Kexiang, Wang Xue, et al.. Short-term efficacy of oxymatrine and entecavir combination in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(2): 173-176.
[2]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[3]	Zhang Longyu, Mou Danlei, Li Tongzeng, et al.. Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis [J]. Journal of Practical Hepatology, 2023, 26(2): 210-213.
[4]	Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.
[5]	Li Yanfen, Zhang Xiaowen, Wang Yanru, et al.. Rescuing therapy of obeticholic acid and fibrates in patients with primary biliary cholangitis without complete response to ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 226-229.
[6]	Xu Jing, Liu Kun, Ma Zhufang. Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy [J]. Journal of Practical Hepatology, 2023, 26(2): 234-237.
[7]	Cheng Yang, Zhang Feng, Wang Xixuan, et al.. Comparison of clinical efficacy of carvedilol and propranolol in preventing esophagogastric varices bleeding in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 254-257.
[8]	Li Jiaxing, Wu Lixia, Yin Chenglong, et al.. Laparoscopic splenectomy and pericardial devascularization in treatment of cirrhotics with esophageal varice and its impact on portal hemodynamics [J]. Journal of Practical Hepatology, 2023, 26(2): 258-261.
[9]	Zhang Bin, Zhao Yuliang, Yan Guobei. Efficacy of hUCB-MNC and hUC-MSC transfusion in patients with decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 262-265.
[10]	Zhou Qiujuan, Zhu Yiming, Ma Yuhang, et al.. Improvement of hypersplenism in patients hepatitis B cirrhosis after TIPS and PSE combination treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 266-269.
[11]	Gu Kai, Wu Xiaochen, Zhu Yiming. Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 270-273.
[12]	Gong Cheng, Tian Yinsheng, Liu Shuang. Comparison of two-year survivals in primary liver cancer patients with spontaneous tumor rupture underwent hepatectomy at early or late operation time windows [J]. Journal of Practical Hepatology, 2023, 26(2): 274-277.
[13]	Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.
[14]	Yin Qiushi, Wang Xueguo, Song Qifeng. Comparison of complete laparoscopic left hemihepatectomy and traditional open laparotomy with left hepatic pedicle occlusion in treatment of patients with intrahepatic and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(2): 282-285.
[15]	Shen Yan, Chen Lin. Endoscopic treatment and long-term management of patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 8-10.